Codeine and CYP2D6 Pharmacogenomics

What Is Codeine?

Codeine is an opioid analgesic used to treat mild to moderate pain and, in some formulations, to suppress cough. It is one of the most widely prescribed opioids globally and is available in many countries both by prescription and in low-dose combination products.

What makes codeine uniquely important in pharmacogenomics is that it is a prodrug. Codeine itself has relatively weak opioid activity. To produce its analgesic effect, it must be converted to morphine in the liver by the enzyme the CYP2D6 enzyme. This means the pain-relieving effectiveness of codeine depends almost entirely on your CYP2D6 metabolizer status — making the codeine–CYP2D6 interaction one of the most clinically significant drug-gene pairs.

How CYP2D6 Converts Codeine to Morphine

After ingestion, codeine undergoes several metabolic pathways. The most clinically important is O-demethylation by CYP2D6, which converts codeine to morphine. Morphine is responsible for the majority of codeine's analgesic effect and also its opioid-related side effects.

Approximately 5–10% of codeine is converted to morphine via this pathway. Although this seems like a small fraction, morphine is far more potent than codeine — approximately 10 times more potent as an opioid receptor agonist. Even small variations in morphine production can have clinically meaningful effects on both pain relief and safety. Learn more about how pharmacogenomic testing works from raw DNA data.

Impact of CYP2D6 Metabolizer Status

Your CYP2D6 phenotype directly determines how much morphine your body produces from codeine:

• Ultrarapid Metabolizer (UM): Increased CYP2D6 activity leads to faster and greater conversion of codeine to morphine. This can result in dangerously elevated morphine levels, potentially causing respiratory depression, excessive sedation, and in severe cases, death. CPIC guidelines recommend avoiding codeine entirely.
• Normal Metabolizer (NM): Standard CYP2D6 function. Codeine is converted to morphine at the intended rate. Standard dosing applies.
• Intermediate Metabolizer (IM): Reduced CYP2D6 activity. Lower morphine production may lead to reduced analgesic effectiveness. Some patients may require alternative pain management.
• Poor Metabolizer (PM): Severely reduced or absent CYP2D6 activity. Very little or no morphine is produced, resulting in minimal analgesic benefit. CPIC guidelines recommend avoiding codeine and using an alternative analgesic.

For a plain-language explanation of these metabolizer categories and how they affect drug response, see what poor metabolizer status means.

FDA Boxed Warning

In 2017, the FDA issued a strengthened boxed warning — its most serious safety communication — restricting codeine use in children under 12 and in adolescents aged 12–18 following tonsillectomy or adenoidectomy. The FDA also warned against codeine use by breastfeeding mothers, as morphine can pass into breast milk at dangerous concentrations in ultrarapid metabolizers.

These warnings followed reports of serious adverse events, including deaths, in children who were CYP2D6 ultrarapid metabolizers. The cases demonstrated how CYP2D6 genetic variation can transform a commonly prescribed medication into a serious safety risk in specific populations.

CPIC Guideline Summary

The codeine–CYP2D6 interaction has a CPIC Level A classification — the strongest evidence level. The CPIC guideline (Crews et al., 2014; PMID: 24458010) provides specific recommendations:

• NM: Standard codeine dosing. Monitor for efficacy and adverse effects as expected.
• IM: Codeine may provide reduced analgesia. If adequate pain relief is not achieved, consider an alternative analgesic not metabolized by CYP2D6.
• PM: Avoid codeine. Use an alternative analgesic such as a non-opioid or an opioid not dependent on CYP2D6 (e.g., morphine, oxycodone). Tramadol and hydrocodone share CYP2D6 dependence and present similar concerns.
• UM: Avoid codeine due to the risk of toxicity from rapid morphine formation. Use an alternative analgesic regardless of clinical indication.

Understanding Your Results

DecodeMyBio does not call CYP2D6 from your raw DNA data, so it cannot report a CYP2D6 diplotype, activity score, or metabolizer phenotype for codeine. CYP2D6 phenotype depends heavily on gene deletions, duplications, and hybrid alleles that need a specialized caller a consumer genotyping array does not provide — we will not invent a result we can't support. Your Decode+ medication results will tell you this plainly for codeine.

Because codeine safety depends directly on CYP2D6 status, this is exactly the kind of case where clinical-grade testing with copy-number analysis matters — ask your prescriber about it if codeine (or tramadol) is being considered. See our methodology for how results are derived, our limitations page for important caveats, and our guide to understanding your report. To see how DecodeMyBio compares with other pharmacogenomic services, visit our pharmacogenomic testing comparison.

Related Resources

• Tramadol and CYP2D6 — the same prodrug problem, prescribed more often
• CYP2D6 gene — variants, phenotypes, and clinical context
• Metoprolol and CYP2D6 — same gene affects this common beta-blocker
• CYP2D6 poor metabolizer — the signs and what to do
• What does poor metabolizer mean?
• What to do with your 23andMe raw data

Frequently Asked Questions